Several studies have tested MIF inhibitors or MIF blocking antibodies to decrease inflammation in diseases such as sepsis and autoimmune diabetes [25], [47], and thus, the same approach could be tested in colon cancer. Here, MIF is linked to malignant colon neoplasm.